54 billion U.
S.
dollars, and its net profit was 3.
696 billion U.
S.
dollars.
As of September 10, 2020, the total market value of the group company is as high as 165.
5 billion US dollars, ranking in the forefront of instrument companies.
Products mainly include analytical instruments , laboratory equipment, reagents, consumables and software, etc.
, providing comprehensive laboratory solutions to serve customers in all walks of life, covering the four major brands of hermo Scientific, Life Technologies, Fisher Scientific and Unity™ Lab Services series.
At that time, the thermoelectric company had a keen insight into the wide range of requirements for environmental monitoring equipment , so the thermoelectric company established a department to develop air pollution monitoring equipment.
In 1977, the thermoelectric company separated the department into the environmental instrument department, which also became the profitable business unit of the thermoelectric company at that time.
6 billion U.
S.
dollars to make a large-scale merger and acquisition of Fisher Scientific.
The two companies formally merged, and the thermoelectric company was renamed Thermo Fisher Scientific (Thermo Fisher Scientific).
At that time, the annual revenue of thermal power was only US$2.
63 billion, while the annual revenue of Fisher was as high as US$5.
58 billion.
The Thermo Fisher M&A drama began.
1 billion on the acquisition of Diane.
In the same year, it acquired Lomb Scientific.
6 billion.
From *chip company Affymetrix, to real-time X-ray diffraction provider INEL, and even electron microscope company FEI, to stem cell company MTI-GlobalStem.
Among them, Affymetrix, as a gene chip industry*, developed the world's first gene chip as early as 1989.
Affymetrix's GeneChip biochip detection system is *a chip system approved by the European Union and the US FDA for in vitro diagnosis.
2 billion; at the same time, it acquired FEI, a manufacturer of electron microscopes.
7 billion in cash.
5 billion.
The acquisition is a large-scale medical industry merger that has been announced so far this year.
Its revenue and market value are among the top in the instrument industry.
Thermo Fisher has developed strategic cooperation with local Chinese enterprises and institutions in food testing, genetic testing, technical support, laboratory construction, cell therapy, tumor diagnosis, and mass spectrometry.
Accelerate the deployment of equipment and other fields, and continue to increase the market share of its products and services in the Chinese market.
Its headquarters in China is in Shanghai, and branches have been established in Beijing, Guangzhou, Hong Kong, Chengdu, Shenyang, Xi’an, Nanjing, Wuhan, Kunming, etc.
The number of employees More than 4,000; In order to meet the needs of the Chinese market, the existing 6 factories have set up 5 application development centers in Shanghai, Beijing and Suzhou at the same time to bring cutting-edge technologies and products to Chinese customers.
The three parties will jointly build the Global Innovation Institute of Cryo-EM for Drug Discovery (CDD).
The two parties will work together to build a modern and efficient testing laboratory.
The two parties will carry out in-depth cooperation on the construction of school-level public platforms and professional laboratories in the Western Science and Technology Innovation Port of Xi’an Jiaotong University-Wisdom Learning Town (hereinafter referred to as "Innovation Port"), and jointly build the "Xi'an Jiaotong University-Thermo Fisher Scientific" Innovative Technology Joint Laboratory".
The two parties promised to jointly develop a new generation of tumor clinical detection products through a strong alliance and complementary advantages in the future.
In this strategic cooperation, the two parties will establish a joint laboratory based on the Nano and Microstructure Research Center (NRC) of Wuhan University of Technology to further improve the productivity of scientific laboratories.
The two parties promised to go hand in hand to jointly promote the localized production of clinical mass spectrometers and related supporting equipment, thereby accelerating the application and popularization of clinical mass spectrometry technology in China.
The two parties will work together to build a modern and efficient testing laboratory, and the two parties will also cooperate in the joint development of testing methods and applications, and the training and development of testing talents.
The two parties will cooperate in the field of laboratory operation and construction.
, Ltd.
reached a strategic cooperation.
The two parties will carry out in-depth cooperation in the field of tumor in vitro diagnostics, committed to the research and development of tumor companion diagnostic products, and accelerate the development of tumor genetic testing services.
The implementation of China's clinical oncology market will better benefit cancer patients.
, Ltd.
signed a strategic cooperation agreement.
The two parties will jointly build a gene therapy joint base in Shanghai Zhangjiang Science City (Shanghai Medical Park), relying on Thermo Fisher's advantages in products, technologies, and integrated services in the field of cell and gene therapy, and jointly promote the industrialization and industrialization of gene therapy in China.
Commercial development.